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Abstract 
Regarding the widespread and ever-increasing applications of biomaterials in different medical fields, 
their accurate assessment is of great importance. Hence the safety and efficacy of biomaterials is 
confirmed only through the evaluation process, the way it is done has direct effects on public health. 
Although every biomaterial undergoes rigorous premarket evaluation, the regulatory agencies receive 
a considerable number of complications and adverse event reports annually. The main factors that 
challenge the process of biomaterials evaluation are dissimilar regulations, asynchrony of biomaterials 
evaluation and biomaterials development, inherent biases of postmarketing data, and cost and timing 
issues. Several pieces of evidence indicate that current medical device regulations need to be improved 
so that they can be used more effectively in the evaluation of biomaterials. This article provides 
suggested conceptual refinements and practical reforms to increase the efficiency and effectiveness of 
the existing regulations. The main focus of the article is on strategies for evaluating biomaterials in US, 
and then in EU. 
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Introduction 
Biomaterials: Definition, Classification and Applications 
Although there are several instances that have historically demonstrated the use of man-made 
structures as artificial organs in ancient times, the science and engineering of biomaterials has only a 
half-century history.1 There is not a consensus over the definition of biomaterials among authors. In 
the past, biomaterials were defined as “non-vital materials used in medical devices, intended to 
interact with biological systems.” In this definition, biomaterials were considered as a structural 
component of medical devices and their evaluation was a part of the evaluation process of medical 
devices. In the newer definition, biomaterial is any material (other than drugs) that interacts with living 
tissues and performs a “particular function” without causing adverse effects.2,3 Particular functions 
intended for biomaterials include (1) measurement of biomarkers and diagnosis of diseases, (2) 
enhancement of tissue functions, and (3) total/partial substitution of a damaged tissue or organ. In this 
definition, biomaterials are considered as an independent category of medical devices that require the 
accurate recognition of their types, features, and applications to allow appropriate evaluation. 
Traditionally, biomaterials have been classified based on their chemical composition into metallic, 
polymeric, ceramic, and composite biomaterials.4 This kind of classification is simple, but it is neither 
all-encompassing nor technically beneficial. Merely limiting the widespread scope of biomaterials to 
metallic, polymeric, ceramic, and composite will lead to ignorance of the definitive characteristics of 
these diverse and ever-growing classes of medical devices. In general, because of the direct contact of 
biomaterials with living tissues, characteristics that describe the type and duration of the biomaterial-
tissue interactions should be considered in their classification. 
In the past, biomaterials were mainly used for substitution of tissues damaged by disease or traumas. 
Nevertheless, in the last 2 decades, advances in fabrication and characterization of materials on one 
hand, and the evolution of regenerative strategies in medicine alongside with groundbreaking 
successes in cellular and molecular biology and genetics on the other hand, provided a substrate in 
which new classes of biomaterials with innovative applications were developed. The emerging 
biomaterials are not only intended to restore the structure and function of damaged tissues but also to 
regenerate them via active and targeted interactions. Tissue engineering scaffolds, injectable 
hydrogels, and delivery vehicles for cells, genes, and drugs are examples of emerging biomaterials.5,6 
Biomaterials Evaluation 
Biomaterials evaluation encompasses the assessment of their safety and performance. As stated in 
FDA’s Medical Device User Fee Act (MDUFA) and EU Regulation on Medical Devices, safety and 
performance of medical devices are of equal importance and should be taken into account 
concurrently and conjointly.7,8 
The safety of a biomaterial should be viewed from a risk management perspective, and its complete 
life span should be considered in order to analyze its associated risks. Generally, not only the 
biomaterial but also its potential degradation products and sterilization residuals should not cause any 
harmful local or systemic effects in host tissues. A wide range of in vitro and in vivo tests may be used 
to evaluate cytotoxicity, genotoxicity, pyrogenicity, local effects following implantation, 
hemocompatibility, sensitization potential and systemic toxic effects of biomaterials. If further 
information on the carcinogenicity or reproductive/developmental toxicity is published, they will also 
be considered. In very rare cases, additional tests are also carried out if required by regulators.9 
Several methods have been developed and standardized to study each of the above-mentioned 
potential effects of biomaterials. For example, hemocompatibility is assessed via hemolysis, medical 
device–mediated complement activation and thrombogenicity. Furthermore, there are several ways to 
perform a special test. For instance, hemolytic properties of (bio)materials could be tested according to 
the guidelines of ASTM F 756-00. However, some researchers believe that ASTM F 756-00 is developed 
to test the hemolytic properties of specific materials, so blood compatibility of whole medical devices 
cannot be evaluated merely via this standard. These researchers suggest to implement ASTM F756-00 
as a starting point to develop a protocol for hemolysis test.10,11 
Among different available approaches, ISO 10993 standards provide a framework of guidelines for 
biological safety assessment of medical devices. ISO 10993 is composed of 20 parts. Table 
1 summarizes the title and the last version of each parts. 
Table 1. ISO 10993 Series of Standards for Evaluating Biological Safety of Medical Devices. 
Part Number Title Last Updated Version Reference 
1 Evaluation and testing within a risk management process 2009 12 
2 Animal welfare requirements 2006 13 
3 Tests for genotoxicity, carcinogenicity, and reproductive toxicity 2014 14 
4 Selection of tests for interactions with blood 2002 15 
5 Tests for in vitro cytotoxicity 2009 16 
6 Tests for local effects after implantation 2016 17 
7 Ethylene oxide sterilization residuals 2008 18 
8 Selection and qualification of reference materials for biological tests 2001 19 
9 Framework for identification and quantification of potential degradation products 1999 20 
10 Tests for irritation and skin sensitization 2010 21 
11 Tests for systemic toxicity 2006 22 
12 Sample preparation and reference materials 2012 23 
13 Identification and quantification of degradation products from polymeric medical devices 1998 24 
14 Identification and quantification of degradation products from ceramics 2001 25 
15 Identification and quantification of degradation products from metals and alloys 2000 26 
16 Toxicokinetic study design for degradation products and leachables 1997 27 
17 Establishment of allowable limits for leachable substances 2002 28 
18 Chemical characterization of materials 2005 29 
19 Physicochemical, morphological, and topographical characterization of materials 2006 30 
20 Principles and methods for immunotoxicology testing of medical devices 2006 31 
22 Guidance on nanomaterials 2017 32 
33 Guidance on tests to evaluate genotoxicity—Supplement to ISO 10993-3 2015 33 
 
On the other hand, every biomaterial is manufactured for a specific purpose. The clinical effectiveness 
of a biomaterial is proved only when it can produce the intended effect(s) for the relevant medical 
condition. To demonstrate the claimed performance of a biomaterial, its technical functions should be 
verified as well. For instance, in parts 2 and 3 of ISO 5840, material properties and mechanical features 
that affect the performance of heart valve substitutes are declared.34,35 Guidelines on test methods 
and acceptable values for each of the functional attributes are also given in these standards. 
Biomaterials Evaluation Procedures 
The evaluation of biomaterials is performed in accordance with the process used to evaluate medical 
devices. That is why sometimes biomaterials and medical devices are used as interchangeable terms in 
the following. 
Biomaterials evaluation process divides into premarket evaluation and postmarket surveillances. US 
and EU, as the largest biomaterials markets, implement somewhat different routes for biomaterials 
evaluation. 
Premarket evaluation 
The Food, Drug, and Cosmetics Act (FD&C Act) has established FDA regulations for medical devices to 
ensure their safety and performance. Generally, for a given biomaterial to be sold in US, whether it has 
been manufactured in US or not, a marketing application is submitted to be reviewed by Center for 
Devices and Radiological Health (CDRH).36 FDA evaluates biomaterials based on their level of risk (Table 
2). 
Table 2. FDA’s Risk-based Classification of Medical Device.37 
 
Class Level of 
Risk 
Description Approval Requirements Examples 
I Low Simple, well established, with minimal controls for 
user 
General controls Wound dressing, zinc oxide-eugenol 
dental cement 
II Medium Simple to medium complexity, with existing 
products on the market 
General controls and special 
controls 
Nonabsorbable surgical suture, Gutta 
Percha 
III High New technology or life-supporting General controls and premarket 
approval 




• Almost all class III biomaterials are subject to premarket approval (PMA) application. 
• If “substantial equivalence” is available for a class II biomaterial, a 510(k) notification should be 
submitted. Substantial equivalence means that the safety and performance of the new medical 
device is similar to a device that is already on the market (a predicate device). In other words, it 
is possible for a newer version of an existing biomaterial to enter the market in a less 
cumbersome way via 510(k) submission. The 510(k) does not mandate manufacturers to 
perform clinical trials; thus, it is a less stringent process than PMA evaluation. 
• Most of the biomaterials in class I are exempt from premarket evaluation. However, the safety 
of all biomaterials must be established in any case. In the case of in vitro diagnostic devices, 
biocompatibility assessment is not required. Because they do not directly or indirectly contact 
the body.38,39 
 
The European Medical Device Regulation was implemented in May 2017. In the EU, local private for-
profit organizations called Notified Bodies are responsible for the evaluation of medical devices. 
Regulation of biomaterials (and medical devices) in Europe is based on Medical Device Directives 
(MDDs), including Active Implantable Medical Device Directive (AIMDD 90/385/EE), Medical Device 
Directive (MDD 93/42/EEC), and In Vitro Diagnostic Medical Device Directive (IVDMDD 98/79/EC).8 
The main criterion of a biomaterial to be approved in the EU is that its benefits outweigh its risks, and 
it possesses the claimed performance.40 Once a biomaterial is approved, it can hold a CE (Conformity 
European) mark, and only in this case can it be available in the European market. 
In the EU, the selection of the appropriate procedure to evaluate a biomaterial is determined based on 
the biomaterial’s class of risk. There are some differences between classification of biomaterials in US 
and EU. The EU classification has determined that class I refers to “low risk” biomaterials which are 
non-invasive and have no interaction with body tissues. Class IIa and IIb are the biomaterials with 
“medium risk.” The level of invasiveness of the biomaterials in the Class IIb are higher, thus they are 
subject to more special controls. Biomaterials in the Class III are high risk and scientific review of their 
safety and performance is required during their premarket approval procedure (Table 3). The 
conformity assessment of Class III biomaterials is similar to class IIb, except their approval is dependent 
on the submission of design documents and relevant technical files to be completely reviewed by the 
Notified Bodies.40,41 
Table 3. Conformity Assessment Route and the Related Annexes of the Directive 93/42/EEC, as 
Amended for the Assessment of Different Classes of Biomaterials in EU.41 
 Biomaterial’s Class      
Related Annexes  I I Sterile I Measure IIa IIb III 
II (– section 4)  • • • •  
II (+ section 4)      • 
III     • • 
IV  • • • • • 
V  • • • • • 
VI  • • • •  
VII • • • •   
 
Generally, for medical devices requiring full PMA, EU evaluations require less time than FDA processes. 
In 2012, California Healthcare Institute and Boston Consulting Group conducted a comparative study 
on 46 medical devices approved through PMA. The study revealed that evaluations in EU last on 
average 3 years less than the US. However, the approval lag time between US and EU is much less for 
510(K) and class I devices.42 
Postmarket surveillances 
After the release of biomaterials in the American or European markets, postmarket surveillances are 
performed to assess their long-term safety. Because clinical trials are not mandatory for the approval 
of all biomaterials, postmarket surveillances are of great importance in long-term evaluations of safety 
and performance. Another reason to perform postmarket surveillances is because clinical trials 
inherently cannot detect some “adverse events” because of the limited number of enrolled subjects or 
the limited time that could be allocated for clinical trials.43 
One among many examples that illustrates the need to perform biomaterials postmarket surveillances 
is “very late stent thrombosis (VLST)” of drug-eluting coronary stents. VLST is a catastrophic event that 
could lead to the patient’s death. It occurs at least one year after the implantation of the biomaterial 
via percutaneous coronary intervention; thus, it is unlikely to be demonstrated with premarket 
evaluation.44 
In the US, based on Section 522 of the Federal Food, Drug and Cosmetic Act, FDA has the authority to 
mandate manufacturers to perform postmarket surveillances if their products belong to class II or III 
and meet any of the following conditions: 
1. The failure of the device could cause severe health consequences. 
2. The device is planned to be implanted in the body for at least 1 year. 
3. The device has a significant use in kids. 
4. The device is a “life-sustaining” or “life-supporting” device and is used outside a device user 
facility.43 
 
Special programs are developed to facilitate the postmarket surveillance of medical devices in the US. 
Manufacturers and consumers of medical devices report adverse events by Medical Device Report and 
Med Watch programs, respectively.45,46 When postmarket surveillances find potential complications in 
a device, safety alerts are issued by the FDA to patients and clinicians. If the studies reflect systemic 
concerns about a device, the manufacturer must conduct a recall. According to FDA, “A recall is an 
action taken to address a problem with a medical device that violates FDA law. Recalls occur when a 
medical device is defective, when it could be a risk to health, or when it is both defective and a risk to 
health.”47 
Recalls do not necessarily mean that the device should not be used anymore; rather it could simply 
indicate the device needs to be checked, adjusted, or fixed. 
To better perform postmarket surveillances, device manufacturers are required to mark the devices 
with a unique device identifier (UDI). UDI facilitates the traceability of devices and accelerates the 
identification of devices with adverse events. Information about devices that hold UDI are available via 
the Global UDI Database (GUDID).48 
In the EU, after a biomaterial’s safety and performance is approved by a Notified Body, its postmarket 
surveillances is conducted under the supervision of a Competent Authority (CA). The basic principles to 
perform postmarket surveillances are outlined by Medical Device Directives. Further details and 
templates for collecting data and reporting adverse events are provided by Non-Binding European 
Commission guidance documents. Recall data and adverse event reports gathered by CAs are 
submitted to the European Databank on Medical Devices (EUDAMED). EUDAMED enables information 
transfer between CAs and the European Commission’s Enterprise and Industry Directorate General.49 
In order to reduce the risk of death or to avoid endangering the patient’s health, manufacturers take 
Field Safety Corrective Actions (FSCAs) in the case of the defective approved devices. Based on the 
level of the risk caused by device malfunction, appropriate actions (varied from changes in labeling to 
complete removal from the market) will be taken.50 
Examples of Why Biomaterials Evaluation Processes Need to Be Improved 
In March 2010, French Agency for the Safety of Health Products (AFSSAPS) removed breast implants 
manufactured by Poly Implant Prothèse (PIP) from the market. Further investigations revealed that PIP 
implants were made of a nonmedical silicone gel without “biocompatibility” assessment of the 
material. The PIP scandal was not publicized until a middle-aged recipient of PIP died of an infrequent 
cancer called Anaplastic Large-Cell Lymphoma (ALCL). The number of PIP implant recipients estimated 
30,000, in France alone.51,52 
In August 2010, Articular Surface Replacement (ASR) hip implants produced by DePuy were recalled 
from the market. The number of ASR implants sold previously was more than 93,000 units. This was 
despite the several individual and organizational reports that have declared complications related to 
ASR implants earlier. For example, the Australian National Joint Replacement Registry report in 2007 
indicated that the revision rate of ASR implants was higher than the expected rate for hip arthroplasty 
revisions (5.16% to 1%, respectively).53,54 
The above examples occurring in the same year reveal that pre- and postmarket vigilance of 
biomaterials need to be improved. 
Challenges in Biomaterials Evaluation 
Evaluation of medical devices in general, and biomaterials in particular, is a challenging process. The 
following are the current challenges of biomaterials evaluation: 
1. Asynchrony of biomaterials evaluation and biomaterials development: Evaluation of 
biomaterials has not kept pace with the development of new biomaterials. According to the 
“Innovation or Stagnation” report issued by FDA in 2004: “Not enough applied scientific work 
has been done to create new tools to get fundamentally better answers about how the safety 
and effectiveness of new products can be demonstrated.”55 
2. Dissimilar regulations: Approval requirements for a specific biomaterial are not the same in 
different regulatory systems. For example, the minimum clearance criterion of FDA for 
GuardWire—a coronary guidewire with an elastomeric balloon used in angioplasty—was a 
multicenter randomized controlled trial performed on 800 patients.56 Meanwhile, the European 
Regulator required PercuSurge, the manufacturer of Guardwire, to perform a 22-patient study 
with no control group.57 Dissimilar regulations for a specific product makes development of 
biomaterials a costly and time-consuming process. Recent ISO refinements, particularly in 
biological assessment of medical devices, has increased the consistency between ISO and FDA 
guidelines. However, there is still not an overall standard approach covering all classes of 
medical devices. Remaining inconsistencies in evaluation procedures is still the main source of 
confusing and inefficient assessment processes.58 
3. Inherent biases of postmarketing data: There is no guarantee that the data provided to the 
regulatory agencies by health associate professionals or manufacturers are free of bias. Adverse 
events may not be reported transparently and accurately. Therefore, it is better not to rely on 
this information unconditionally. FDA uses Medical Device Reporting (MDR) to collect 
information and assess the risks associated with marketed devices. According to the FDA: 
“Although MDRs are a valuable source of information, this passive surveillance system has 
limitations, including the potential submission of incomplete, inaccurate, untimely, unverified, 
or biased data. In addition, the incidence or prevalence of an event cannot be determined from 
this reporting system alone due to potential under-reporting of events and lack of information 
about frequency of device use.”59 
4. Costs and timing: There is no doubt that improving the quality of human life is dependent on 
innovative medical solutions. The evaluation of biomaterials should be not only accurate but 
also agile and economically beneficial. In 2010, the data from a survey of over 200 American 
companies in the field of medical technology showed that the approximate cost for a low- to 
moderate-risk medical device to be cleared via 510(k) was US$31 million. The average cost to 
bring a high-risk device “from concept to clearance” via PMA was approximately US$94 million. 
The participants also claimed that they should experience a 31-month review time for their new 
products from the first communication to clearance.60 Regarding the significant approval costs 
and prolonged delays in FDA compared to the corresponding processes in the EU, FDA critics 
argue that the US will no longer be able to compete in global medical device markets.61 
Costs and timing-related issues do not only decelerate the development of new 
biomaterials, but also hinder the availability of new drugs. Developing new antiviral vaccines 
requires an average of 8 to 12 years and US$2 billion.62 This demonstrates that global health is 
not prepared to confront the emerging threats. 
 
Discussion 
In order to improve biomaterials evaluation, the following conceptual refinements and practical 
reforms are suggested: 
Conceptual refinements: An inclusive classification of biomaterials is essential to cover key 
aspects and provide profound insights about the completely different types and interactions of 
biomaterials with surrounding tissues. In other words, the inclusive classification is one of the 
prerequisites to establish efficient regulations for biomaterials evaluation. In Table 4, a number 
of criteria to classify the biomaterials is suggested, which provides a broad overview of classic 
and emerging biomaterials. For instance, classification based on structural integrity divides 
biomaterials into porous biomaterials and nonporous biomaterials. These 2 classes of 
biomaterials have distinctive interactions with surrounding tissues. For example, it has been 
well demonstrated that in porous implants with pore diameters ≥100 μm, bone ingrowth 
facilitates implant fixation. On the contrary, in nonporous implants and implants with smaller 
pores, a loose fibrous capsule forms at the interface, which increases the risk of failure. 
Therefore, in porous biomaterials, porosimetry analysis should be used to measure pore 
parameters including volume, size, interconnectivity, and distribution.63 
Table 4. Classification of Biomaterials. 
Classification Basis  Classes of Biomaterials 
Chemical composition  Metallic, polymeric, ceramic, composite 
Origin  Natural, synthetic, hybrid (semisynthetic) 
Dimensions  Macrometric, micrometric, nanometric 
Interaction with living tissues Bioinert, bioactive 
Biodegradability  Biostable, biodegradable 
Structural integrity  Porous, nonporous 
Aim of application  Diagnostic, therapeutic, preventive, restorative, regenerative 
Site of application  Extracorporeal, intracorporeal 
Duration of contact with body Limited (≤1 d), prolonged (>1 d and <30 d), permanent (>30 d) 
The left column is the basis used for the classification of biomaterials and the right column is the 
classes of biomaterials regarding the classification basis indicated in the adjacent column. 
Following the revolutionary advancements in biomaterial science and technology in the last 2 decades, 
it seems that the definitions of some of the key concepts should be updated in a unified manner. 
One of the key concepts that indicates the biological safety of biomaterials is biocompatibility. In 
1980s, biocompatibility was defined as “the ability of a material to perform with an appropriate host 
response in a specific application.”64 This ambiguous and imprecise definition is not practically useful 
and does not distinguish between different classes of biomaterials with diverse natures of interactions 
and durations of contact with host tissues. 
It had been demonstrated in early 1973 that the biological reactions to poly(2-hydroxyethyl 
methacrylate) in its porous and solid form are completely different. The surrounding tissue isolates the 
solid polymer by fibrotic avascular capsule formation, while the tissue integrates to the polymer with 
30- to 40-μm pores with a much less fibrosis and much more vascularization. Recently, Buddy D. 
Ratner65 addressed an important question about these 2 completely different biological reactions: 
“The only word that we have for these two tissue reactions is biocompatible. The healing reactions are 
so different. How can we call both biocompatible?” 
Consequently, he proposed 2 definitions based on the biological reactions to the implanted materials: 
“Biotolerability is the ability of materials to reside in the body for long periods of time with only low 
degrees of inflammatory reaction.…Biocompatibility is the ability of materials to locally trigger and 
guide normal wound healing, reconstruction, and tissue integration.” 
From Ratner’s point of view, the majority of existing biomaterials that are approved routinely by 
regulatory agencies are biotolerable, while the emerging biomaterials that are able to integrate with 
tissues via rigorous vascularization are biocompatible.65 
Concisely, the assessors of biomaterials should be thoroughly aware of unique and distinctive aspects 
of biomaterials. On the other hand, since it seems that biomaterial innovation is in its heyday, the 
assessors should also be able to refurbish their knowledge on biomaterial innovation and 
advancements quickly and continuously. Although it is not easy to be synchronized with the ever 
increasing innovations in the field of biomaterials, establishing closer links between universities, 
research centers, and assessors would facilitate knowledge transfer and help the assessors to update 
their knowledge through periodic training courses. 
Regardless of the reactions of scientific communities, these suggestions are considered to be 
invaluable and thought-provoking because they provide a more accurate and discriminative view about 
the biomaterials. 
Practical Reforms 
1. Integration and harmonization of regulations: In order to overcome the difficulties caused by 
dissimilar regulations, the Global Harmonization Task Force on Medical Devices (GHTF) was 
formed. GHTF covers all classes of medical devices, including biomaterials, and aims to speed 
up coordination and convergence of international regulations.66 In addition to partnerships 
between relevant organizations, it seems that the political will of the major players of the 
biomaterial market is also needed to establish a global evaluation system and to accelerate the 
processes that lead to the uniformity of treatment. 
2. Innovators-regulators close collaborations: Patients need to reach the most innovative medical 
products and solutions in a timely manner. Collaborations between the innovators and the 
regulators should be optimized in order to address this demand. In 2011, FDA designed the 
Innovation Pathway to “shorten the time and reduce the costs from concept to 
commercialization for innovative medical devices.”67 Regional hubs for innovation and 
evaluation that would operate based on harmonized regulatory procedures could facilitate the 
approval processes of new biomaterials. These centers might be established by mutual 
investment of neighboring countries. 
3. Universal Biomaterials Databases (UBDs): During the last 2 decades, biomaterials have 
attracted great interest from researchers. Nowadays, vast amounts of scientific knowledge are 
available to describe different types of biomaterials, their properties and applications. Building 
up and developing universal databases to gather data and results from previously published 
and ongoing scientific publications that address the interactions of different materials with 
living tissues is an efficient way to drive biomaterials evaluations faster and in a more 
economically beneficial way. Knowledge from prior research could accelerate ongoing studies 
by avoiding redundancy.68 It could also be beneficial for manufacturers by reducing product 
development costs and time. Obviously, the transfer of knowledge and experience between 
researchers and manufacturers can be more effective when it becomes a reciprocal process. 
However, manufacturers may not be willing to share their knowledge because of market 
competition. This barrier can be eliminated by respecting intellectual property rights and 
providing financial incentives for manufacturers. Clearly, active participation of all involved 
parties expedite the process of biomaterials research and development. 
 
Conclusion 
The number and variety of biomaterials on the market has increased dramatically in recent years. 
These innovative products have improved life quality of patients all over the world. However, 
evaluation of biomaterials according to the existing medical device assessment regulations faces 
challenges that needs to be addressed. To remove these challenges, conceptual refinements and 
practical reforms are necessary. It can be concluded that improvement of biomaterials evaluation 
principally requires a collaborative effort between all interested parties including researchers, 
manufacturers and regulators. 
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